BACKGROUND: Large granular lymphocyte leukemia is a rare lymphoproliferative disorder associated with autoimmune diseases and impaired hematopoiesis. This study describes the clinical and biological characteristics of 229 patients with T-cell or NK-cell large granular lymphocyte leukemia. DESIGN AND METHODS: The diagnosis was based on a large granular lymphocyte expansion (> 0.5x10(9)/L) lasting more than 6 months. Monoclonal T-cell receptor gamma gene rearrangement was detected in all the cases of T-cell large granular lymphocyte leukemia. Patients with chronic NK-cell lymphocytosis had an indolent disease, while those with multiorgan large granular lymphocyte infiltration and an aggressive clinical disease were considered to have NK-cell large granular lymphocyte leukemia. RESULTS: The diagnosis of T-cell large granular lymphocyte leukemia was confirmed in 201 cases, chronic NK-cell lymphocytosis in 27 cases and NK-cell large granular lymphocyte leukemia in one case. Associated autoimmune diseases or other neoplasms were present in 74 and 32 cases, respectively. One hundred patients (44%) required treatment, mainly for neutropenia-associated infections (n=45), symptomatic autoimmune diseases (n =24), transfusion-dependant anemia (n=18), and other causes (n=13). Patients were treated with steroids (n= 33), methotrexate (n=62), cytoxan (n=32), or cyclosporine (n=24) either as first-, second-, third- or fourth-line therapy. The overall response rate at 3 months and complete response rate for the various treatments were as follows: steroids (12% and 3%), methotrexate (55% and 21%), cytoxan (66% and 47%), cyclosporine (21% and 4%), respectively. Four out of 13 patients responded to splenectomy. Eleven out of 15 patients responded to cytoxan after methotrexate treatment had failed. The mean number of treatments was 3.4 (range, 1-7). There were 15 large granular lymphocyte leukemia-related deaths. CONCLUSIONS: Patients with T-cell large granular lymphocyte leukemia and chronic NK-cell lymphocytosis have similar clinical and biological features and responses to treatment. First-line therapy with cytoxan should be tested in a prospective trial.
BACKGROUND: Large granular lymphocyte leukemia is a rare lymphoproliferative disorder associated with autoimmune diseases and impaired hematopoiesis. This study describes the clinical and biological characteristics of 229 patients with T-cell or NK-cell large granular lymphocyte leukemia. DESIGN AND METHODS: The diagnosis was based on a large granular lymphocyte expansion (> 0.5x10(9)/L) lasting more than 6 months. Monoclonal T-cell receptor gamma gene rearrangement was detected in all the cases of T-cell large granular lymphocyte leukemia. Patients with chronic NK-cell lymphocytosis had an indolent disease, while those with multiorgan large granular lymphocyte infiltration and an aggressive clinical disease were considered to have NK-cell large granular lymphocyte leukemia. RESULTS: The diagnosis of T-cell large granular lymphocyte leukemia was confirmed in 201 cases, chronic NK-cell lymphocytosis in 27 cases and NK-cell large granular lymphocyte leukemia in one case. Associated autoimmune diseases or other neoplasms were present in 74 and 32 cases, respectively. One hundred patients (44%) required treatment, mainly for neutropenia-associated infections (n=45), symptomatic autoimmune diseases (n =24), transfusion-dependant anemia (n=18), and other causes (n=13). Patients were treated with steroids (n= 33), methotrexate (n=62), cytoxan (n=32), or cyclosporine (n=24) either as first-, second-, third- or fourth-line therapy. The overall response rate at 3 months and complete response rate for the various treatments were as follows: steroids (12% and 3%), methotrexate (55% and 21%), cytoxan (66% and 47%), cyclosporine (21% and 4%), respectively. Four out of 13 patients responded to splenectomy. Eleven out of 15 patients responded to cytoxan after methotrexate treatment had failed. The mean number of treatments was 3.4 (range, 1-7). There were 15 large granular lymphocyte leukemia-related deaths. CONCLUSIONS:Patients with T-cell large granular lymphocyte leukemia and chronic NK-cell lymphocytosis have similar clinical and biological features and responses to treatment. First-line therapy with cytoxan should be tested in a prospective trial.
Authors: A W Langerak; R van Den Beemd; I L Wolvers-Tettero; P P Boor; E G van Lochem; H Hooijkaas; J J van Dongen Journal: Blood Date: 2001-07-01 Impact factor: 22.113
Authors: M Lima; J Almeida; A H Santos; M dos Anjos Teixeira; M C Alguero; M L Queirós; A Balanzategui; B Justiça; M Gonzalez; J F San Miguel; A Orfão Journal: Am J Pathol Date: 2001-11 Impact factor: 4.307
Authors: T Lamy; F A Bauer; J H Liu; Y X Li; E Pillemer; H Shahidi; S A Gregory; R Zambello; R Marcolongo; G Semenzato; T P Loughran Journal: Br J Haematol Date: 2000-03 Impact factor: 6.998
Authors: Margarida Lima; Julia Almeida; Maria Dos Anjos Teixeira; Maria del Carmen Alguero Md; Ana Helena Santos; Ana Balanzategui; Maria Luís Queirós; Paloma Bárcena; Antonio Izarra; Sónia Fonseca; Clara Bueno; Benvindo Justiça; Marcos Gonzalez; Jesús F San Miguel; Alberto Orfao Journal: Am J Pathol Date: 2003-08 Impact factor: 4.307
Authors: T Marchand; T Lamy; H Finel; W Arcese; S Choquet; J Finke; A Huynh; G Irrera; D Karakasis; J Konopacki; J Lambert; M Michieli; H C Schouten; W Schroyens; G Sucak; J Tischer; E Vandenberghe; P Dreger Journal: Leukemia Date: 2015-09-22 Impact factor: 11.528
Authors: Hanna L M Rajala; Thomas Olson; Michael J Clemente; Sonja Lagström; Pekka Ellonen; Tuija Lundan; David E Hamm; Syed Arshi Uz Zaman; Jesus M Lopez Marti; Emma I Andersson; Andres Jerez; Kimmo Porkka; Jaroslaw P Maciejewski; Thomas P Loughran; Satu Mustjoki Journal: Haematologica Date: 2014-10-03 Impact factor: 9.941
Authors: HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran Journal: Curr Hematol Malig Rep Date: 2020-04 Impact factor: 3.952
Authors: E Poullot; R Zambello; F Leblanc; B Bareau; E De March; M Roussel; M L Boulland; R Houot; A Renault; T Fest; G Semenzato; T Loughran; T Lamy Journal: Ann Oncol Date: 2014-08-05 Impact factor: 32.976